DOP2005000013A - Formas polimórficas de 4,5,6,7-tetrahidroisoxazolo[5,4-c]piridin-3-ol - Google Patents

Formas polimórficas de 4,5,6,7-tetrahidroisoxazolo[5,4-c]piridin-3-ol

Info

Publication number
DOP2005000013A
DOP2005000013A DO2005000013A DO2005000013A DOP2005000013A DO P2005000013 A DOP2005000013 A DO P2005000013A DO 2005000013 A DO2005000013 A DO 2005000013A DO 2005000013 A DO2005000013 A DO 2005000013A DO P2005000013 A DOP2005000013 A DO P2005000013A
Authority
DO
Dominican Republic
Prior art keywords
tetrahydroisoxazolo
piridin
polymorphic forms
new crystalline
gaboxadol
Prior art date
Application number
DO2005000013A
Other languages
English (en)
Spanish (es)
Inventor
Vincent Brett Cooper
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31971783&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2005000013(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of DOP2005000013A publication Critical patent/DOP2005000013A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DO2005000013A 2004-01-30 2005-01-28 Formas polimórficas de 4,5,6,7-tetrahidroisoxazolo[5,4-c]piridin-3-ol DOP2005000013A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0402118.4A GB0402118D0 (en) 2004-01-30 2004-01-30 Polymorphic forms of a GABAA agonist

Publications (1)

Publication Number Publication Date
DOP2005000013A true DOP2005000013A (es) 2005-08-15

Family

ID=31971783

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2005000013A DOP2005000013A (es) 2004-01-30 2005-01-28 Formas polimórficas de 4,5,6,7-tetrahidroisoxazolo[5,4-c]piridin-3-ol

Country Status (34)

Country Link
US (2) US7262300B2 (https=)
EP (2) EP2042505A1 (https=)
JP (1) JP4917440B2 (https=)
KR (1) KR101210361B1 (https=)
CN (1) CN1914212B (https=)
AR (1) AR047511A1 (https=)
AT (1) ATE414088T1 (https=)
AU (1) AU2005209473B2 (https=)
BR (1) BRPI0506858A (https=)
CA (1) CA2554536C (https=)
CO (1) CO5700743A2 (https=)
CY (1) CY1108647T1 (https=)
DE (1) DE602005010975D1 (https=)
DK (1) DK1713813T3 (https=)
DO (1) DOP2005000013A (https=)
EA (1) EA009413B1 (https=)
EC (1) ECSP066735A (https=)
ES (1) ES2314613T3 (https=)
GB (2) GB0402118D0 (https=)
HR (1) HRP20080614T3 (https=)
IL (1) IL176863A0 (https=)
MA (1) MA28364A1 (https=)
MX (1) MXPA06008595A (https=)
MY (1) MY139525A (https=)
NO (1) NO20063843L (https=)
NZ (1) NZ548191A (https=)
PE (1) PE20050769A1 (https=)
PL (1) PL1713813T3 (https=)
PT (1) PT1713813E (https=)
SI (1) SI1713813T1 (https=)
TW (1) TWI345972B (https=)
UA (1) UA87487C2 (https=)
WO (1) WO2005073237A2 (https=)
ZA (1) ZA200605307B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
US8268866B2 (en) 2004-03-29 2012-09-18 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US20060063802A1 (en) 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US9072662B2 (en) 2004-03-29 2015-07-07 Auris Medical Ag Methods for the treatment of tinnitus induced by cochlear excitotoxicity
DE102005004343A1 (de) * 2005-01-25 2006-08-10 Eberhard-Karls-Universität Tübingen Universitätsklinikum Behandlung von Phantomphänomenen
EP1848420A4 (en) 2005-01-28 2008-01-23 Merck & Co Inc POLYMORPH SHAPES OF A GABAA AGONIST
KR101271263B1 (ko) 2005-09-28 2013-06-07 아우리스 메디칼 아게 내이 장애 치료용 약학 조성물
CN102093387B (zh) * 2009-12-10 2012-07-25 天津泰普医药知识产权流转储备中心有限公司 4,5,6,7-四氢异噁唑并[5,4-c]吡啶-3-醇一水合物的晶型化合物
WO2013087090A1 (en) 2011-12-12 2013-06-20 Auris Medical Ag Treatment of tinnitus through modulation of chloride co-transporter nkcc1 in the auditory system
EP4541420A3 (en) 2015-07-17 2025-06-25 Ovid Therapeutics Inc. Methods of treating developmental disorders with gaboxadol
EP3481387A4 (en) 2016-08-11 2020-04-08 Ovid Therapeutics Inc METHOD AND COMPOSITIONS FOR TREATING EPILEPTIC DISEASES
CN110225754A (zh) * 2016-11-22 2019-09-10 奥维德医疗公司 用氟吡汀治疗发育障碍和/或癫痫发作紊乱的方法
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
JP2020529440A (ja) 2017-08-04 2020-10-08 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 糖尿病および関連する状態の処置におけるガボキサドールの使用
WO2020061410A1 (en) 2018-09-20 2020-03-26 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering
JP2022514194A (ja) 2018-11-21 2022-02-10 セルテゴ セラピューティクス インコーポレイテッド 自殺のリスクを低減し、うつ病を迅速に軽減するためのガボキサドール
WO2020131856A1 (en) 2018-12-17 2020-06-25 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
US11364228B2 (en) 2019-12-18 2022-06-21 Ovid Therapeutics Inc. Gaboxadol for therapeutic treatment of 1p36 deletion syndrome
MX2022014599A (es) 2020-05-20 2022-12-16 Certego Therapeutics Inc Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos.

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK270378A (da) 1977-06-20 1978-12-21 Krogsgaard Larsen P Isoxazolderivater
US4315934A (en) 1979-09-24 1982-02-16 Sandoz Ltd. Organic compounds
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4352731A (en) * 1980-11-03 1982-10-05 Occidental Research Corporation Apparatus for selective wetting of particles
DE19525598C2 (de) 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
UA52661C2 (uk) * 1996-06-14 2003-01-15 Ново Нордіск А/С Безводна кристалічна форма гідрохлориду r(-)-n-(4,4-ди(3-метилтієн-2-іл)бут-3-еніл) ніпекотинової кислоти
EP1220658A1 (en) 1999-09-28 2002-07-10 H. Lundbeck A/S Melt granulated composition and modified release dosage form prepared from said composition
AR031473A1 (es) 2000-11-20 2003-09-24 Lundbeck & Co As H Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
BR0209820A (pt) 2001-05-18 2004-06-01 Lonza Ag Processo para a preparação de formulações sólidas de 3-hidróxi-3-metilbutirato de sódio
AU2002338855B2 (en) 2001-05-21 2007-08-16 H. Lundbeck A/S Granular preparations of gaboxadol
WO2004022550A1 (en) * 2002-09-03 2004-03-18 Naturon Limited Compound for treatment of anxiety and methods of preparation and use thereof
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
BRPI0410857A (pt) * 2003-06-25 2006-07-04 Lundbeck & Co As H método para o tratamento de depressão, uso de gaboxadol, e, composição farmacêutica
AR045540A1 (es) * 2003-09-05 2005-11-02 Lundbeck & Co As H Metodo de elaboracion de 4,5,6,7 tetrahidroisoxazol [5,4-c] piridin-3-ol (thip)
US20070032553A1 (en) 2003-09-10 2007-02-08 Mckernan Ruth Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
TW200528098A (en) 2003-12-18 2005-09-01 Lundbeck & Co As H Treatment of insomnia in human patients
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
MXPA06015196A (es) 2004-06-29 2007-03-15 Lundbeck & Co As H Tratamiento del dolor neuropatico, la fibromialgia o la artritis reumatoide.
GB0417558D0 (en) 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
EP1848420A4 (en) 2005-01-28 2008-01-23 Merck & Co Inc POLYMORPH SHAPES OF A GABAA AGONIST
WO2006102093A1 (en) 2005-03-18 2006-09-28 Transform Pharmaceuticals, Inc. Gaboxadol forms, compositions thereof, and related methods
US20080262029A1 (en) 2005-04-29 2008-10-23 H. Lundbeck A/S Acid and Base Salt Forms of Gaboxadol

Also Published As

Publication number Publication date
US8236958B2 (en) 2012-08-07
GB2410434A (en) 2005-08-03
CO5700743A2 (es) 2006-11-30
AU2005209473B2 (en) 2010-03-04
DK1713813T3 (da) 2009-02-16
GB0402118D0 (en) 2004-03-03
AR047511A1 (es) 2006-01-25
TWI345972B (en) 2011-08-01
IL176863A0 (en) 2006-10-31
WO2005073237A3 (en) 2005-10-20
CY1108647T1 (el) 2014-04-09
PE20050769A1 (es) 2005-10-04
UA87487C2 (ru) 2009-07-27
KR20070007070A (ko) 2007-01-12
EP1713813B1 (en) 2008-11-12
CN1914212A (zh) 2007-02-14
AU2005209473A1 (en) 2005-08-11
EP1713813A2 (en) 2006-10-25
JP4917440B2 (ja) 2012-04-18
ATE414088T1 (de) 2008-11-15
GB0501847D0 (en) 2005-03-09
MXPA06008595A (es) 2006-08-28
CA2554536A1 (en) 2005-08-11
ZA200605307B (en) 2007-11-28
MA28364A1 (fr) 2006-12-01
TW200534856A (en) 2005-11-01
SI1713813T1 (sl) 2009-02-28
DE602005010975D1 (de) 2008-12-24
HK1096547A1 (en) 2007-06-01
ES2314613T3 (es) 2009-03-16
KR101210361B1 (ko) 2012-12-10
WO2005073237A2 (en) 2005-08-11
HRP20080614T3 (en) 2009-01-31
US20070259912A1 (en) 2007-11-08
US20050171142A1 (en) 2005-08-04
EA009413B1 (ru) 2007-12-28
CN1914212B (zh) 2010-10-06
ECSP066735A (es) 2006-10-31
US7262300B2 (en) 2007-08-28
PL1713813T3 (pl) 2009-04-30
JP2007519697A (ja) 2007-07-19
NZ548191A (en) 2010-04-30
EA200601404A1 (ru) 2006-12-29
EP2042505A1 (en) 2009-04-01
PT1713813E (pt) 2008-12-26
MY139525A (en) 2009-10-30
CA2554536C (en) 2012-09-18
NO20063843L (no) 2006-08-29
BRPI0506858A (pt) 2007-05-29

Similar Documents

Publication Publication Date Title
DOP2005000013A (es) Formas polimórficas de 4,5,6,7-tetrahidroisoxazolo[5,4-c]piridin-3-ol
DK3880676T3 (da) 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-on-derivater som hpk1-inhibitorer til behandling af cancer
CO2021014022A2 (es) Compuestos de 4h-pirrolo[3,2-c]piridin-4-ona
CA2520979A1 (en) Formulations of ecteinascidins
CR10743A (es) Derivados de azaadamantano y metodos de uso de los mismos
DE60335717D1 (de) Azabicyclo-octan und nonan derivate mit ddp-iv hemmender wirkung
HRP20070429T3 (en) Crystal form of asenapine maleate
WO2006002097A3 (en) Retinal derivatives and methods for the use thereof for the treatment of visual disorders
GT200600264A (es) Modificaciones cristalinas de piraclostrobina
SV2008002542A (es) Formas solidas cristalinas de tigeciclina y metodos para preparar los mismos ref. 01142.0379-00267 (am101946sv)
PA8577201A1 (es) 3-fenil-propionamido, 3-fenil-acrilamido y derivados 3-fenil-propinamido como inhibidores de mao-b
CO2020007895A2 (es) Inhibidores de histona acetiltransferasa de la familia myst
WO2019229536A3 (en) Novel benzodiazepine derivatives and uses thereof
PA8652701A1 (es) Derivados de quinolina e isoquinolina 5-sustitutos, un procedimiento para su preparacion y su uso como inhibidores de la inflamacion
DE60308836D1 (de) Ophthalmische zubereitung mit ascomycin
ECSP077306A (es) Derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparación y su uso como antiinflamatorios
PA8577601A1 (es) Derivados aldehido de polietilenglicol
DK1838683T3 (da) Fremgangsmåde til fremstilling af [1,4,5]-oxadiazepinderivater
UY29434A1 (es) Derivados de tetrahidronaftalina, procedimientos para su preparación y su uso como inhibidores de la inflamacinn
DK3763718T3 (da) Substitueret 3,4,12,12a-tetrahydro-1h-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazin-6,8-dion, farmaceutisk sammensætning og fremgangsmåder til fremstilling og anvendelse deraf
GT200500340A (es) Derivados de octahidropirrolo [3,4-c] pirrol
ECSP056038A (es) Procedimiento para la preparación de un polimorfo de maleato de rosiglitazona
ECSP088517A (es) Procedimiento para la preparacion del inhibidor del ciclo celular-779 cristalino y purificado
WO2005007279A3 (en) Compounds for changing the physical properties of ice and methods of use thereof
DK3740492T3 (da) 1,2,3',5'-tetrahydro-2'h-spiro[indol-3,1¿-pyrrol[3,4-c]pyrrol]-2,3'-dionforbindelser som terapeutiske midler til aktivering af tp53